Squarepoint Ops LLC Increases Stock Position in argenx SE (NASDAQ:ARGX)

Squarepoint Ops LLC grew its holdings in shares of argenx SE (NASDAQ:ARGX) by 24.5% during the fourth quarter, HoldingsChannel.com reports. The institutional investor owned 22,664 shares of the company’s stock after buying an additional 4,464 shares during the period. Squarepoint Ops LLC’s holdings in argenx were worth $13,938,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. GeoWealth Management LLC lifted its position in argenx by 56.3% during the 4th quarter. GeoWealth Management LLC now owns 50 shares of the company’s stock valued at $31,000 after acquiring an additional 18 shares during the period. Whipplewood Advisors LLC bought a new position in shares of argenx during the fourth quarter valued at approximately $37,000. Global Retirement Partners LLC lifted its holdings in shares of argenx by 369.2% during the fourth quarter. Global Retirement Partners LLC now owns 61 shares of the company’s stock valued at $38,000 after purchasing an additional 48 shares during the last quarter. FIL Ltd purchased a new position in shares of argenx during the fourth quarter valued at approximately $38,000. Finally, Point72 Asia Singapore Pte. Ltd. bought a new stake in shares of argenx in the 4th quarter worth approximately $38,000. 60.32% of the stock is owned by hedge funds and other institutional investors.

argenx Stock Down 0.6%

Shares of NASDAQ ARGX opened at $581.44 on Friday. The firm’s 50-day moving average price is $590.25 and its 200-day moving average price is $612.93. argenx SE has a 52-week low of $358.80 and a 52-week high of $678.21. The company has a market cap of $35.50 billion, a PE ratio of -660.73 and a beta of 0.57.

argenx (NASDAQ:ARGX) last issued its earnings results on Thursday, May 8th. The company reported $2.58 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.32 by $0.26. The company had revenue of $1.35 billion for the quarter, compared to analysts’ expectations of $748.34 million. argenx had a negative net margin of 2.11% and a negative return on equity of 1.45%. As a group, equities research analysts anticipate that argenx SE will post 3.13 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of research analysts recently weighed in on ARGX shares. William Blair reaffirmed an “outperform” rating on shares of argenx in a research report on Friday, February 28th. Guggenheim lowered their price target on argenx from $1,100.00 to $1,065.00 and set a “buy” rating for the company in a research report on Friday, May 9th. Baird R W upgraded shares of argenx from a “hold” rating to a “strong-buy” rating in a research note on Tuesday, May 13th. Wedbush restated an “outperform” rating and set a $715.00 price objective on shares of argenx in a research note on Friday, April 11th. Finally, JMP Securities set a $699.00 target price on shares of argenx in a report on Wednesday, May 14th. One analyst has rated the stock with a hold rating, twenty have given a buy rating and two have issued a strong buy rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of “Buy” and an average target price of $698.11.

argenx Company Profile

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren’s syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis.